Abstract 4143
Background
Cancer incidence is increasing but cancer survival is improving. The life expectancy of PLWHIV also increases with improved HAART, so it is to be expected that PLWHIV are likely to develop a second primitive cancer. It is known that the risk of second cancer is slightly higher after a first cancer and depends on several parameters: the location of the first cancer (the risk is higher after H&N, lung cancer or Hodgkin’s lymphoma) and environmental risk factors such as tobacco or alcohol intake but few studies are available nowadays on this subject. PLWHIV have a high risk of cancer: what for a second cancer incidence?
Methods
The files of 601 patients presented at the multidisciplinary meeting of the CANCERVIH network were reviewed. CANCERVIH is a national "rare cancers" network, accredited by the French National Cancer Institute. For all these patients, the history of cancer, indicated by the referring physicians, was examined. History of cancer that was neither metastasis nor locoregional relapse was considered a first primitive cancer. Cancers developing in the same location were considered as first primitive cancers only if they were considered in complete response at least 5 years before and no relapse was detected in the meantime.
Results
Of the 601 patients reviewed, 72 (12%) had a history of at least one cancer. Fourteen (2,3%) patients had at least 2 previous cancers. For one it was his 7th cancer’s case.Table:
2036P
First cancer (number of patients) | Number of secondary cancer(s) (number of patients) |
---|---|
Kaposi (25) | 1 (23) 2 (2) |
NHL (7) | 1 (5) 2 (2) |
Anal canal (6) | 1 (2) 2 (3) 3 (1) |
Prostate (6) | 1 (4) 2 (1) 6 (1) |
Breast (5) | 1 (5) |
Head and Neck (5) | 1 (4) 4 (1) |
Hodgkin lymphoma (4) | 1 (4) |
Kidney (4) | 1 (3) 2 (1) |
Skin melanoma (3) | 1 (2) 2 (1) |
Eye (2) | 1 (1) 3 (1) |
Anal margin (1) | 1 (1) |
Lung (1) | 1 (1) |
Ovary (1) | 1 (1) |
Large intestine (1) | 2 (1) |
Liver (1) | 1 (1) |
Conclusions
In this study, the initial locations at risk of second cancer seems to concern primarily AIDS defining cancer and among the non-AIDS defining cancers, anal cancer appeared the first one ahead breast and head and neck cancers, showing the importance of maintaining permanent immuno-virological control in these patients’ population: such results confirm the need to maintain and emphasize prevention and screening programs in this high cancer risk population including for those with a sustained undetectable HIV viral load and/or immune restoration.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3930 - Safety profile of tepotinib in patients with advanced solid tumors: pooled analysis of phase I and II data
Presenter: Thomas Decaens
Session: Poster Display session 1
Resources:
Abstract
5373 - Drug-drug interaction profile of tepotinib with CYP3A and P-gp substrates
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
5455 - Bioavailability of tepotinib: impact of omeprazole and food
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
2618 - Tislelizumab Exposure-Response Analyses of Efficacy and Safety in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2563 - Population Pharmacokinetics of Tislelizumab in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2021 - The Addition of Metformin to Systemic Anticancer Therapy
Presenter: Jung Han Kim
Session: Poster Display session 1
Resources:
Abstract
5243 - Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients
Presenter: Antoine Italiano
Session: Poster Display session 1
Resources:
Abstract
598 - Analysis of the overall survival and main surrogates used for FDA approvals in solid and hematological malignancies.
Presenter: Maria Kleniewska-Wieczor
Session: Poster Display session 1
Resources:
Abstract
5381 - Comparison of intratumoral docetaxel exposure in cancer patients between nanoparticle entrapped docetaxel (CPC634) and conventional docetaxel (Cd): the CriTax study
Presenter: Ruben Van Eerden
Session: Poster Display session 1
Resources:
Abstract
2935 - Correlation of progression free survival-2 and overall survival in solid tumors
Presenter: Paul Mainwaring
Session: Poster Display session 1
Resources:
Abstract